VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

1. Class action lawsuit filed against VTRS for securities law violations. 2. Allegations include misrepresentation regarding FDA warning letter impacts. 3. Lawsuit pertains to investor losses during August 2024 to February 2025. 4. Investors can join the lawsuit until June 3, 2025. 5. Bronstein, Gewirtz & Grossman offers contingency fee representation.

Legal

80

4m saved

Insight

Article

FAQ

Why Bearish?

Class action lawsuits often lead to negative sentiment and potential financial liabilities. Historical examples show plunges in stock prices following similar legal actions based on misrepresentation claims.

How important is it?

The lawsuit directly implicates VTRS's credibility and financial health, making it significantly impactful.

Why Short Term?

The immediate concern for VTRS investors is the upcoming legal proceedings and potential settlements. Short-term impacts are typical for firms facing class actions as investor confidence wanes.

Related Companies

AMGN PFE RMD

NEW YORK, April 8, 2025 /PRNewswire/ -- Attorney Advertising

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/VTRS.

Case Details

The Complaint alleges that Defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Specifically, the Complaint alleges that Defendants' statements misrepresented the FDA's issuance of a warning letter and its impact on Viatris' operations and that Defendants routinely referred to the impact of the warning letter as a mere "minor headwind" for the Company.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/VTRS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Viatris you have until June 3, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates

on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC